Instructed-assembly of small peptides inhibits drug-resistant prostate cancer cells

14Citations
Citations of this article
10Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Despite multiple new-drug approvals in recent years, prostate cancer remains a global health challenge because of the prostate cancers are resistant to androgen deprivation therapy. Here, we show that a small D-phosphopeptide undergoes prostatic acid phosphatase (PAP)-instructed self-assembly for inhibiting castration-resistant prostate cancer (CRPC) cells. Specifically, the installation of phosphate at the C-terminal of a D-tripeptide results in the D-phosphopeptide. Dephosphorylating the D-phosphopeptide by PAP forms uniform nanofibers that inhibit VCaP, a CRPC cell. A non-hydrolyzable phosphate analogue of the D-phosphopeptide, which shares similar self-assembling properties with the D-phosphopeptide, confirms that PAP-instructed assembly is critical for the inhibition of VCaP. This work, for the first time, demonstrates PAP-instructed self-assembly of peptides for selective inhibiting CRPC cells.

Cite

CITATION STYLE

APA

Feng, Z., Wang, H., Yi, M., Lo, C. Y., Sallee, A., Hsieh, J. T., & Xu, B. (2020). Instructed-assembly of small peptides inhibits drug-resistant prostate cancer cells. Peptide Science, 112(1). https://doi.org/10.1002/pep2.24123

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free